Loading…
Virax Biolabs Group Limited is projected to decline to $4.61 by 2027, a -2% move from its current price of $4.72. VRAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.21 | $4.72 | $5.29 | -0.06% |
| Jul 13 | $4.01 | $4.71 | $5.54 | -0.12% |
| Jul 14 | $3.86 | $4.71 | $5.74 | -0.18% |
| Jul 15 | $3.75 | $4.71 | $5.92 | -0.24% |
| Jul 16 | $3.64 | $4.71 | $6.08 | -0.30% |
| Jul 17 | $3.55 | $4.70 | $6.22 | -0.36% |
| Jul 18 | $3.47 | $4.70 | $6.36 | -0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.47 | $4.70 | $6.36 | -0.42% |
| Week 2 | $3.05 | $4.68 | $7.18 | -0.83% |
| Week 3 | $2.76 | $4.66 | $7.87 | -1.24% |
| Week 4 | $2.53 | $4.64 | $8.50 | -1.65% |
| Week 5 | $2.35 | $4.62 | $9.09 | -2.06% |
| Week 6 | $2.19 | $4.60 | $9.66 | -2.47% |
| Week 7 | $2.06 | $4.58 | $10.21 | -2.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Virax Biolabs Group Limited is a biotechnology company focused on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Founded in 2013 and headquartered in Lanarkshire, United Kingdom, Virax Biolabs Group Limited was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors.
VRAX currently trades at $4.72, with a market cap of $3.76M and a rank of 5339.
The 30-day range is $2.22 to $10.03, and annualized volatility is 200%.
Forecasts show a mixed price outlook over the coming years. The 2026 average price is $4.72 (Sentiment: NEUTRAL), 2027 average $4.61 (NEUTRAL), 2028 average $3.57 (BEARISH), 2029 average $3.37 (BEARISH), 2030 average $3.56 (BEARISH), and 2031 average $3.62 (BEARISH). A recovery appears in 2032-2035 with 2032 average $5.25, 2033 $5.37, 2034 $4.77, 2035 $5.38 (all NEUTRAL).
Longer-horizon outlook shows bullish momentum in 2040 with average $7.46 and 2050 with average $9.01 (Sentiment: BULLISH).
A major floor 97.8% below — a decisive break under it would weaken the trend.
The nearest floor, 41.9% below — buyers have tended to step in here.
The nearest ceiling, 34.7% above — a clean break opens room to run.
A major ceiling 106.6% above — clearing it would confirm fresh momentum.
Key VRAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.95 | Buy | $4.10 | Buy |
| MA 10 | $3.50 | Buy | $3.35 | Buy |
| MA 20 | $1.83 | Buy | $2.38 | Buy |
| MA 50 | $0.846 | Buy | $1.30 | Buy |
| MA 100 | $0.5133 | Buy | $0.8232 | Buy |
| MA 200 | $0.482 | Buy | $0.6925 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.64 | Neutral |
| Stoch RSI (14) | 45.83 | Neutral |
| CCI (20) | 90.07 | Neutral |
| Williams %R (14) | -36.61 | Info |
| MACD (12,26,9) | 0.33 | Buy |
| ROC (12) | 2532.26 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 63.39 | Neutral |
| TRIX (15) | 16.85 | Buy |
| Awesome (5,34) | 2.79 | Buy |
| Ultimate (7,14,28) | 63.68 | Neutral |
| Momentum (10) | 3.94 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 4.79 | Sell |
| ADX (14) | 41.49 | Buy |
| ATR (14) | 0.55 | Info |
Technical sentiment is bullish in the near term. RSI(14) is 50, indicating balanced momentum around the middle of the range.
The 50-day simple moving average (SMA50) is $4.37, and the 200-day simple moving average (SMA200) is $7.85, suggesting tighter near-term price action versus a longer-term trend.
Support is at $2.74 and resistance at $6.36. The 30-day price range spans $2.22 to $10.03, highlighting notable volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.60 | $4.72 | $5.64 | 0% | Neutral | |
| $3.34 | $4.61 | $6.86 | -2% | Neutral | |
| $2.43 | $3.57 | $5.66 | -24% | Bearish | |
| $2.18 | $3.37 | $5.62 | -29% | Bearish | |
| $2.20 | $3.56 | $6.18 | -25% | Bearish | |
| $2.14 | $3.62 | $6.50 | -23% | Bearish | |
| $2.97 | $5.25 | $9.72 | +11% | Neutral | |
| $2.92 | $5.37 | $10.22 | +14% | Neutral | |
| $2.50 | $4.77 | $9.32 | +1% | Neutral | |
| $2.71 | $5.38 | $10.74 | +14% | Neutral | |
| $3.36 | $7.46 | $16.37 | +58% | Bullish | |
| $4.06 | $9.01 | $20.73 | +91% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.60 | $4.72 | $5.51 | +0.00% |
| August 2026 | $3.62 | $4.39 | $5.54 | -7.05% |
| September 2026 | $3.64 | $4.47 | $5.76 | +1.91% |
| October 2026 | $3.42 | $4.26 | $5.58 | -4.76% |
| November 2026 | $3.19 | $4.01 | $5.34 | -5.72% |
| December 2026 | $3.30 | $4.18 | $5.64 | +4.20% |
Click any year to see its month-by-month VRAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Virax Biolabs Group Limited's 2026 outlook centres on $4.72, within a $2.60 to $5.64 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, VRAX could reach as high as $6.86, with a base case around $4.61 and support toward $3.34 — roughly -2% from $4.72. A consolidation phase looks the most probable path here.
Expect VRAX to range from $2.43 to $5.66 through 2028. The $3.57 average target implies a -24% move from current prices. That is -23% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The VRAX price prediction for 2029 points to an average of $3.37 (low $2.18, high $5.62) — a potential decline of -29% on today's $4.72. Expect choppier, lower action through this leg of the cycle.
In 2030, VRAX is projected to trade between $2.20 and $6.18, averaging $3.56 — a potential decline of -25% from today's $4.72. That is up +6% on the projected 2029 average. A cyclical pullback looks likely — prices rarely move in a straight line.
Virax Biolabs Group Limited's 2031 outlook centres on $3.62, within a $2.14 to $6.50 range. That is up +2% on the projected 2030 average. That marks a -23% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2032, VRAX could reach as high as $9.72, with a base case around $5.25 and support toward $2.97 — roughly +11% from $4.72. Price action looks broadly range-bound.
Expect VRAX to range from $2.92 to $10.22 through 2033. The $5.37 average target implies a +14% move from current prices. That is up +2% on the projected 2032 average. A consolidation phase looks the most probable path here.
The VRAX price prediction for 2034 points to an average of $4.77 (low $2.50, high $9.32) — a potential gain of +1% on today's $4.72. Price action looks broadly range-bound.
In 2035, VRAX is projected to trade between $2.71 and $10.74, averaging $5.38 — a potential gain of +14% from today's $4.72. That is up +13% on the projected 2034 average. A consolidation phase looks the most probable path here.
Virax Biolabs Group Limited's 2040 outlook centres on $7.46, within a $3.36 to $16.37 range. That is up +39% on the projected 2035 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2050, VRAX could reach as high as $20.73, with a base case around $9.01 and support toward $4.06 — roughly +91% from $4.72. Buyers look set to stay in control over this stretch.
Investing $1,000 in VRAX today (≈ 211.864407 VRAX) could be worth
$1,909.22
+$909.22 (+91%) by 2050 · US Dollar
Based on the average projected VRAX price of $9.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRAXwould be worth at today's price.
$1,000 invested in VRAX on Jul 10, 2025 (≈ 1,123.595524 VRAX) would be worth
$5,303.37
+$4,303.37 (+430.3%) today · 5.30× · US Dollar
Based on a VRAX entry price of $0.89 vs. today's $4.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.13 | $1,507.99 | +50.8% |
| 1 month ago | $0.177 | $26,666.67 | +2566.7% |
| 3 months ago | $0.104 | $45,384.61 | +4438.5% |
| 6 months ago | $0.342 | $13,801.17 | +1280.1% |
| 1 year ago | $0.89 | $5,303.37 | +430.3% |
| All time (4.0y) ago | $182 | $25.93 | -97.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRAX forecast.
$9.40 is within our bullish range by 2032, but above the base case.
Implied market cap at $9.40: $7.49M
The multi-year forecast shows a difficult stretch through 2027–2031 with Bearish sentiment and average prices around the $3.5 range. The path improves in 2032–2033, where the average prices rise to $5.25 and $5.37, respectively, with Neutral sentiment and modest upside potential (2032 ROI 11.1, 2033 ROI 13.7).
Further stabilization is seen in 2034–2035, with averages of $4.77 and $5.38 and marginal upside (2034 ROI 1.1, 2035 ROI 14). The longer horizon turns bullish again in 2040, where the average price reaches $7.46 (ROI 58) and remains bullish into 2050 with an average of $9.01 (ROI 90.9).
These projections imply significant uncertainty and upside risk, with a notable shift from bearish to bullish episodes across the 2030s and 2040s, and the potential for substantial gains by 2050.
Tap a question to reveal the answer.
2030 forecast: min $2.20, avg $3.56, max $6.18 with ROI -24.6 and sentiment BEARISH.
The projected path shows Neutral in 2026 (avg $4.72) and 2027 (avg $4.61), Bearish through 2031, Neutral again in 2032–2035, and Bullish in 2040 and 2050 (avg $7.46 and $9.01 respectively). These are estimates, not guarantees, and include periods of decline before potential stronger gains.
Yes. The forecast shows max prices of $10.22 in 2033 and $10.74 in 2035, with higher potential later (2040 max $16.37, 2050 max $20.73).
2040 forecast: min $3.36, avg $7.46, max $16.37 with ROI 58 and sentiment BULLISH.
The current price is $4.72.
Virax Biolabs Group Limited Community Discussion
0Share your Virax Biolabs Group Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.